Personalis NeXT Platform: Precision Neoantigen Selection & MRD Detection
Time: 2:30 pm
day: Conference Day One
Details:
The Personalis NeXT Platform integrates deep tumor tissue profiling with ultrasensitive plasma-based monitoring to support neoantigen-based immunotherapy development.
• ImmunoID NeXT delivers comprehensive immunogenomic profiling from tumor tissue, enabling accurate neoantigen selection through validated exome/transcriptome assays, and neoantigen predictions trained on immunopeptidomics data
• NeXT Personal is a tumor-informed, plasma-based assay for detecting molecular residual disease and recurrence earlier, with longitudinal variant tracking for real-time insight into disease progression
• Together, these assays provide a unified view from tumor to circulation, enhancing precision oncology strategies
